Summit Therapeutics flags OS superiority for ivonescimab Phase III
TradingView News reports Summit Therapeutics says its ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.